| 综述 |
|
|
|
|
| 癌症基因治疗技术进展与展望 |
| 刘怡萱1, 边珍2, 马红梅1 |
1. 西藏大学理学院 拉萨 850000;
2. 复旦大学生命科学学院 上海 200433 |
|
| Progress and Prospect of Cancer Gene Therapy |
| LIU Yi-xuan1, BIAN Zhen2, MA Hong-mei1 |
1. College of Science, Tibet University, Lhasa 850000, China;
2. School of Life Science, Fudan University, Shanghai 200433, China |
| [1] Siegel R L, Miller K D, Jemal A. Cancer statistics 2015. CA Cancer J Clic, 2015, 65(1): 5-29.
[2] Coleman M P. Cancer survival: global surveillance will stimulate health policy and improve equity. Lancet, 2014, 383(9916): 564-573.
[3] Emens L A. Chemoimmunotherapy. Cancer J, 2010, 16(4): 295-303.
[4] Rosenberg S A. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Sci Am, 1995, 1(2): 90-100.
[5] Bishop J M. Molecular themes in oncogenesis. Cell, 1991, 64(2): 235-248.
[6] Sen B, Mahadevan B, DeMarini D M. Transcriptional responses to complex mixtures-A review. Mutat Res-Rev Mutat, 2007, 636(1): 144-177.
[7] O'Connor T P, Crystal R G. Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet, 2006, 7(4): 261-276.
[8] Zhang Z L, Zou W G, Luo C X, et al. An aimed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res, 2003, 13(6): 481-489.
[9] Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med, 2013, 19(3): 329-336.
[10] Liu X Y. Cancer targeting gene-viro-therapy: An evolving anti-cancer strategy. Chin J Cnacer Biother, 2015, 22(2): 159-165.
[11] 吴元明,陈苏民. RNA干涉的最新研究进展. 中国生物化学与分子生物学报, 2003, 19(4): 411-417. Wu Y M, Chen S M. Recent advances in RNA interference. Chin J Biochem, 2003, 19(4): 411-417.
[12] Masiero M, Nardo G, Indraccolo S, et al. RNA interference: Implications for cancer treatment. Mol Aspects Med, 2007, 28(1): 143-166.
[13] Kong R, Sun B, Wang S J, et al. An experiment 1 study of gemcitabine inducing pancreatic cancer cell apoptosis potentiated by nuclear factor-kappa B P65 siRNA. Chin J Surg, 2010, 48(2): 128-133.
[14] Tang X, Zhang Q, Nishitani J, et al. Overexpression of human papilloma virus type 16 on coproteins enhance shypwda-inducible factor 1 alpha protein accumulation and vascular ren dothelial growth factor expression in human cervical. Clin Cancer Res, 2007, 13(9): 2568-2576.
[15] Zhang G X, Hou X L, Li B L, et al. Vascular endothelial growth factor receptor targeted RNA interference inhibits growth of human lung adenocarcinoma cells. Acad J Sec Mil Med Univ, 2008, 29(10): 1153-1156.
[16] Castanotto D, Rossi J J. The promises and pitfalls of RNA interference-based therapeutics. Nature, 2009, 457(7228): 426-433.
[17] Zhang L, Huang J, Yang N, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA, 2006, 103(24): 9136-9141.
[18] Chan S P, Slack F J. MicroRNA-mediated silencing inside P-bodies. RNA Biol, 2006, 3(3): 97-100.
[19] 王椋, 赵春华. miRNA与癌症发生. 癌症进展, 2011, 9(2): 124-127. Wang L, Zhao C H. miRNA and carcinogenesis. Oncol Prog, 2011, 9(2): 124-127.
[20] Cimmino A, Calin G A, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting bcl-2. Proc Natl Acad Sci USA, 2005, 102(39): 13944-13949.
[21] Zhang Y, Wang Z, Chen M, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer, 2012, 11(1): 23-32.
[22] Tang F, Zhang R, He Y, et al. MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One, 2012, 7(5): e35435.
[23] Calin G A, Sevignani C, Dumitru C D, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 2004, 101(29): 2999-3004.
[24] Volinia S, Calin G A, Liu C G, et al. A microRNA expression signature of human solid tumors de fines cancer gene targets. Proc Natl Acad Sci USA, 2006, 103(7): 2257-2261.
[25] Kao S C, Fulham M, Wong K, et al. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. Am J Respir Crit Care Med, 2015, 191(12): 1467-1469.
[26] Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science, 2007, 315(5819): 1709-1712.
[27] Markarova K S, Haft D H, Barrangou R, et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol, 2011, 9(6): 467-477.
[28] Barrangou R. RNA-mediated programmable DNA cleavage. Nature Biotechnology, 2012, 30(9): 836-838.
[29] Aubrey B J, Kelly G L, Kueh A J, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep, 2015, 10(8): 1422-1432.
[30] Zetsche B, Gootenberg J S, Abudayyeh O O, et al. Cpf1 is a single RNA-guided endonuclease of class 2 CRISPR-Cas system. Cell, 2015, 163(3): 759-771. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
